Major Publications

• Meziani L, Gerbé de Thoré M, Hamon P, Bockel S, Andrade Louzada A, Clemenson C, Corré E, Liu W , Dupuy C, Mondini M, Deutsch E. “Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages” J Immunother Cancer 2020

ImmunoRadAI

This group belongs to the UMR 1030 Molecular Radiotherapy and Novel Therapeutics

Lab members

Group leader : Pr. Laurence ZITVOGEL

• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Tumour immunology and immunotherapy

Group 1 of the Inserm (National Institute of Health and Medical Research) UMR 1015 research unit, « Tumour immunology and immunotherapy of cancer », is under the direction of Professor Laurence Zitvogel.  Between 2015 and 2018 it will be exploring three lines of research: 
-    Gut microbiota and pro- or anti-tumour inflammatory/immunological activity, by measuring the effect of specific therapies on their regulation,